Syndax Announces Positive Pivotal Topline Results from Relapsed …
2 days ago · Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced positive topline results from the ...
Syndax falls after mid-stage data for leukemia drug - MSN
S yndax Pharmaceuticals (NASDAQ: SNDX) fell ~23% in the premarket on Tuesday after the cancer drug developer reported topline data from a pivotal Phase 2 portion of its AUGMENT-101 trial for ...
Syndax's Revumenib Trial Hits Key Endpoint with 47% Response …
2 days ago · Syndax Pharmaceuticals (SNDX) announced positive topline results from the AUGMENT-101 trial of revumenib in relapsed/refractory mNPM1 AML patients. The trial met its primary endpoint with a 23% complete remission rate (p-value = 0.0014) and achieved a 47% overall response rate in a heavily pre-treated population. The safety profile was favorable, with only 5% of patients discontinuing due to ...
Syndax Pharmaceuticals: Promising Phase 2 Results ... - Markets …
1 day ago · SNDX’s price has also changed moderately for the past six months – from $20.970 to $16.630, which is a -20.70% drop . See Insiders’ Hot Stocks on TipRanks >>
Syndax Pharmaceuticals Stock Falls After Data From Mid-Stage …
2 days ago · Price Action: SNDX stock is down 22.1% at $16.96 at last check Tuesday. Read Next: Home Depot’s Earnings Beat Sets Conservative Tone for FY24, J.P. Morgan Predicts Slowing Deterioration Ahead
Syndax: Fall On NPM1m AML Data Of Revumenib Creates Buy …
2 days ago · Syndax Pharmaceuticals (NASDAQ: SNDX) just reported positive results from the phase 2 portion of its AUGMENT-101m trial evaluating the use of Revumenib for the treatment of patients with relapsed ...
Syndax Pharmaceuticals, Inc. (SNDX) - Yahoo Finance
Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.
Syndax Highlights Recent Updates and Anticipated 2024 Milestones
WALTHAM, Mass., Jan. 2, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today...
Press Releases - Syndax Pharmaceuticals, Inc.
WALTHAM, Mass. , Nov. 1, 2024 /PRNewswire/ -- Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that Michael A. Metzger , Chief Executive Officer of Syndax, as well as members of the Syndax. Read More.
Syndax Pharmaceuticals, Inc. (SNDX) Stock Price, News, Quote …
Find the latest Syndax Pharmaceuticals, Inc. (SNDX) stock quote, history, news and other vital information to help you with your stock trading and investing.